Abstract 4837
Background
Cholangiocarcinoma (CCA), which includes extrahepatic cholangiocarcinoma (exCCA) and intrahepatic cholangiocarcinoma (iCCA), is a primary malignancy which is often diagnosed as advanced stage and inoperable. The poor sensitivity of clinical diagnosis and lack of effective biomarkers to guide treatment are the main problems to be tackled. Identification of new and effective biomarkers is necessary to assist early diagnosis and prognosis of CCA.
Methods
Deep sequencing targeting 450 cancer genes was performed on FFPE and matching blood samples were collected from 63 CCA patients. Genomic alterations (GAs) including single nucleotide variations, short and long insertions and deletions, copy number variations, and gene rearrangements were analyzed. Tumor mutational burden (TMB) was measured by an algorithm developed in-house. The correlation analysis was performed by One-way ANOVA.
Results
A total of 63 (35 male and 28 female) Chinese CCA patients, including 40 intrahepatic CCA (iCCA) and 23 extrahepatic CCA (exCCA), were analyzed in this study. The most commonly altered genes included TP53 (41.27%, 26/63), KRAS (31.75%, 20/63), ARIK1A and IDH1 (15.87%, 10/63, for both), SMAD4 (14.29%, 9/63), FGFR2 and BAP1 (12.70%, 8/63, for both) and CDKN2A (11.11%, 7/63). The mutation of LRP2 specifically occurred with low frequency (7.5%, 3/40) in iCCA patients. There were 24 patients aged 50 to 70 years, 6 patients aged more than 70 years and 10 patients aged less than 50 years (younger group). Notably, the mutations of LRP2 were detected only in the younger group, and statistical analysis showed the significant correlation between LRP2 and younger iCCA patients (P = 0.02). Also, 2 of the 3 patients with LRP2 mutations harbored high TMB (TMB-H, more than 10 Muts/Mb). Statistical analysis showed a significant association of LRP2 and TMB-H.
Conclusions
The mutation of LRP2 is associated with younger Chinese iCCA patients. The correlation of LRP2 and TMB-H represents a better mutational burden and probably a better prognosis of younger iCCA patients with LRP2 mutations. Our results support that LRP2 may be a potential biomarker for the diagnosis and prognosis of younger Chinese iCCA patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract